Revlimid 10MG cap
Ended Awarded Last action
- Contract number
- 36C26026F0170
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $0
Award facts
- Contract value
- $0.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$22,629 | |
| Original award | $22,629 |
About this award
Bristol-Myers Squibb Company, a global biopharmaceutical manufacturer, received a delivery order award from the Department of Veterans Affairs' Veterans Integrated Service Network 20 on January 30, 2026, to supply REVLIMID 10mg capsules. The contract is a firm fixed-price delivery order with a ceiling value of approximately $22.6K and an ultimate completion date of March 31, 2026. This award was issued under Bristol-Myers Squibb's Federal Supply Schedule contract (36F79724D0101) on the Pharmaceuticals and Drugs (FSS-61-IB) master schedule, which carries a substantial ceiling value of $12.3 billion and extends through April 30, 2029. No set-aside designation was applied to this award, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer.
The delivery order supports the VA's mission to provide advanced oncology and specialty pharmaceutical treatments to eligible veterans. REVLIMID is a critical specialty oncology product within Bristol-Myers Squibb's portfolio, which also includes CAR T cell therapies and other hematologic malignancy treatments. The VA has issued more than fifty documented delivery orders to Bristol-Myers Squibb since 2022 across multiple Veterans Integrated Service Networks, demonstrating sustained demand for the company's specialized cancer treatments and immunotherapy products that represent current standards of care in oncology.
Quick answers
Who was awarded contract 36C26026F0170?
36C26026F0170 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 20 (Veterans Health Administration) on January 30, 2026.
How much is contract 36C26026F0170 worth?
The government has obligated $0 on 36C26026F0170.
Is contract 36C26026F0170 an order under another contract?
Yes. 36C26026F0170 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26026F0170 competed?
The extent of competition for 36C26026F0170 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award